ProQR Therapeutics N.V. filed a Form 6-K/A with the SEC on October 30, 2026, amending four previously filed foreign private issuer reports solely to incorporate their contents by reference into the company's active Form F-3 registration statements.

Key Highlights

  • Amendment purpose: The filing amends four original reports filed on August 13, 2026 (two reports), September 9, 2026, and September 23, 2026.
  • Incorporation by reference: Information from each original report, including exhibits, is incorporated into five Form F-3 registration statements.
  • Registration file numbers: The five F-3 filings carry File Nos. 333-282419, 333-270943, 333-263166, 333-285767, and 333-297272.
  • Scope limited: According to the filing, this amendment does not amend, update, or restate any information in the original reports, nor does it reflect events occurring after their original filing dates.
  • Signed by: Dennis Hom, Chief Financial Officer of ProQR Therapeutics N.V., signed the filing on October 30, 2026.

ProQR Therapeutics Connects Prior Disclosures to Active Registration Statements

ProQR Therapeutics N.V., a Netherlands-based biopharmaceutical company listed on NASDAQ:PRQR and headquartered at Zernikedreef 9, 2333 CK Leiden, The Netherlands, filed this Form 6-K/A to link a series of earlier periodic disclosures to its existing shelf registration infrastructure. The company files its annual reports under Form 20-F, as indicated on the cover of this filing.

According to the filing, the amendment's sole purpose is to cause the content of four original Form 6-K reports to be incorporated by reference into five Form F-3 registration statements, which may include prospectuses forming part of those statements. The filing specifies that incorporated information applies only to the extent it is not superseded by documents or reports subsequently filed or furnished. No new substantive disclosures about ProQR's clinical programs, financial results, or business operations were made in this amendment itself.

What Was Disclosed

ProQR Therapeutics N.V. filed a Form 6-K/A on October 30, 2026, amending four prior periodic reports to incorporate their content by reference into five active Form F-3 registration statements, without amending or restating any original information.